Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 4

Infliximab (Remicade) in the treatment of psoriatic arthritis

Authors Philip Mease

Published 15 December 2006 Volume 2006:2(4) Pages 389—400

Philip Mease
Seattle Rheumatology Associates, Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, USA
Abstract: Elucidation of the cellular immunopathology and cytokine profile of psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, has resulted in the development of a number of novel biologic therapies. Among these biologics, tumor necrosis factor-alpha (TNF-á) inhibitors have been used successfully to treat patients suffering from rheumatoid arthritis or psoriasis. The pivotal role of TNF-á in the pathogenesis and progression of PsA suggested that anti-TNF-á agents could be effective in controlling PsA. The results from two large, randomized, double-blind, placebo-controlled trials in patients with moderate to severe PsA indicated that the anti-TNF- inhibitor, infliximab, can control both the joint and skin manifestations of the disease. This review focuses on the clinical development of infliximab as a treatment for PsA. The development of other anti-TNF-á biologics is also discussed.
Keywords: psoriatic arthritis, psoriasis, spondyloarthropathies, TNF inhibition, biologics

Download Article [PDF] 

Readers of this article also read:

Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model

Carin A Uyl-de Groot, Joseph McDonnell, Guul ten Velde, David Radice, Harry J M Groen

Therapeutics and Clinical Risk Management 2006, 2:317-323

Published Date: 15 September 2006

An assessment of the cost-utility of therapy for psoriasis

Stefan C Weiss, Wingfield Rehmus, Alexa B Kimball

Therapeutics and Clinical Risk Management 2006, 2:325-328

Published Date: 15 September 2006

Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease – a case series

Madeleine Nowak, Petra Büttner, Simone Harrison, Kym Daniell, Beverly Raasch, Rick Speare

Therapeutics and Clinical Risk Management 2006, 2:329-334

Published Date: 15 September 2006